POS0906 PREVALENCE OF SLEEP DISTURBANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS WITHIN THE AUSTRALIAN CLINICAL SETTING (ASLEEP STUDY): A REAL-WORLD OBSERVATIONAL STUDY USING THE OPAL DATASET

Background: Sleep disorders are more prevalent in patients with ankylosing spondylitis (AS) compared to the general population. disturbance AS, addition pain and fatigue, can lead impaired physical function reduced quality of life. Objectives: The primary objective was determine prevalence sleep AS a real-world Australian cohort using Insomnia Severity Index (ISI) Multivariate Apnoea Prediction (MAPI). ISI score ≥ 15 is considered clinical insomnia. MAPI values below 0.05 suggestive apnoea. Methods: Routinely collected, de-identified data were sourced from OPAL dataset. Patients aged between 18 95 years diagnosis who had completed at least one or questionnaire Jan-2019 Sept-2020 included. questionnaires emailed OPAL’s electronic patient reported outcome (ePRO) delivery method clinic smart device returned patient’s file QR code. Disease activity assessed BASDAI collected same time as questionnaires. Age, sex duration symptoms used propensity match Il-17ai TNFi group 1:2 ratio. Results: 495 5,323 identified included analysis (n=395 TNFi, n=48 (secukinumab), n=52 other therapies). 142 matched population (n = 94 n 48 Il-17ai). In overall mean (SD) age 48.3 (13.6), 55.4% males, BMI 30.1 (19.6) index date 4.8% depression. 51.7% an optimal disease control (BASDAI <4). 8.6 (6.2). 48.1% no significant insomnia, 32.7% subthreshold 16% insomnia (moderate severity) 3.2% (severe). 0.4 (0.3). 292 (59.0%) low risk apnoea, 134 (27.1%) high apnoea 69 13.9% not questionnaire. scored population, groups scores 9.1 (6.6) 8.9 (5.9) index, respectively (p 0.83) 0.3 (0.2) (0.3) (p=0.046), however higher percentage overweight obese treatment group. Ordered logistic regression relationship demographics found that ≥4 seven times likely experience greater (OR 7.29, 95%CI 2.37 22.46, p=0.001) than those <4. Conclusion: this cohort, poor associated disturbance, despite bDMARD therapy. Little difference observed treatment. Screening for fatigue routine care may provide holistic view burden disease. Table 1. Patient characteristics index. (n=94) (n=48) p value category Underweight 2 (2%) 1 0.094 Normal weight 33 (35%) 8 (17%) Overweight 24 (26%) 16 (33%) Obese 27 (29%) 21 (44%) Missing (9%) (4%) Duration (months), 61.0 (156.7) 23.7 (20.1) 0.18 <4 43 (46%) 23 (48%) 0.89 > 4 35 (37%) 17 score, 0.83 (%) No clinically 44 (57%) (50%) Subthreshold 30 (32%) (31%) Clinical (moderate) (16%) (severe) 5 (5%) 0.046 MAPI, Yes (18%) 0.051 62 (66%) 26 (54%) 6 (12%) Acknowledgements: authors acknowledge members Rheumatology Ltd their providing study, Software4Specialists Pty Audit4 platform. We WriteSource Medical statistical services. Funding study provided by Novartis. Disclosure Interests: Kathleen Tymms: None declared, Belinda Butcher: Tracey Sletten: Tegan Smith: Catherine OSullivan: Geoff Littlejohn Consultant of: AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Novartis, Pfizer, Janssen, Sandoz, Sanofi Seqirus., Ricky Sadler Employee Current employee Rebecca Tronnberg Hedley Griffiths Novartis Lilly.